Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy

被引:29
作者
Barker, IK
Crawford, SM
Fell, AF
机构
[1] UNIV BRADFORD,SCH PHARM,CANC MED RES UNIT,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND
[2] UNIV BRADFORD,SCH PHARM,PHARMACEUT ANAL RES UNIT,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND
来源
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1996年 / 681卷 / 02期
关键词
epirubicin; epirubicinol; 7-deoxydoxorubicinone; 7-deoxydoxorubicinolone; 4'-epidoxorubicinone; doxorubicinone; doxorubicinolone;
D O I
10.1016/0378-4347(96)00030-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In order to determine epirubicin and its metabolites at low concentrations (<38 ng/ml) in small plasma samples, a fast reliable method based on a precipitation pre-treatment and sensitive reversed-phase isocratic HPLC has been developed and validated for epirubicin in the range 5-100 ng/ml. The R.S.D. was 5-9% over this concentration range. For human serum containing 25 ng/ml of epirubicin, the inter- and intra-day variation was <10%. Recoveries of the metabolites epirubicinol, 7-deoxydoxorubicinone and 7-deoxydoxorubicinolone at 20 ng/ml ranged from 94-104%. The assay has been used to study human plasma samples taken during a 96-h infusion of epirubicin in a patient with multiple myeloma. The combined levels of the unseparated metabolites, epirubicin glucuronide and epirubicinol glucuronide, were semiquantitatively determined after treatment with beta-glucuronidase. The metabolites epirubicinol and 7-deoxydoxorubicinolone, but not 7-deoxydoxorubicinone, were also detected and measured.
引用
收藏
页码:323 / 329
页数:7
相关论文
共 16 条
[1]   A SENSITIVE AND SIMPLE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF DOXORUBICIN AND ITS METABOLITES IN PLASMA [J].
ANDERSEN, A ;
WARREN, DJ ;
SLORDAL, L .
THERAPEUTIC DRUG MONITORING, 1993, 15 (05) :455-461
[2]   EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS [J].
BARLOGIE, B ;
SMITH, L ;
ALEXANIAN, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) :1353-1356
[3]  
BRENNER DE, 1984, CANCER TREAT S, V3, P77
[4]   RAPID HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR THE ANTHRACYCLINES DAUNORUBICIN AND 7-CON-O-METHYLNOGAROL IN PLASMA [J].
BROWN, JE ;
WILKINSON, PA ;
BROWN, JR .
JOURNAL OF CHROMATOGRAPHY, 1981, 226 (02) :521-525
[5]   CLINICAL AND PHARMACOKINETIC STUDY OF 96-H INFUSIONS OF DOXORUBICIN IN ADVANCED CANCER-PATIENTS [J].
BUGAT, R ;
ROBERT, J ;
HERRERA, A ;
PINEL, MC ;
HUET, S ;
CHEVREAU, C ;
BOUSSIN, G ;
ROQUAIN, J ;
CARTON, M .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (03) :505-511
[6]  
CASSINELLI G, 1984, DRUG METAB DISPOS, V12, P506
[7]  
DEESEN PE, 1984, DRUG METAB DISPOS, V12, P9
[8]   INVITRO CHEMOSENSITIVITY TESTING USING THE MULTICELLULAR TUMOR SPHEROID MODEL [J].
KERR, DJ ;
WHELDON, TE ;
KERR, AM ;
KAYE, SB .
CANCER DRUG DELIVERY, 1987, 4 (02) :63-73
[9]   REDUCTION OF DOXORUBICIN CARDIOTOXICITY BY PROLONGED CONTINUOUS INTRAVENOUS-INFUSION [J].
LEGHA, SS ;
BENJAMIN, RS ;
MACKAY, B ;
EWER, M ;
WALLACE, S ;
VALDIVIESO, M ;
RASMUSSEN, SL ;
BLUMENSCHEIN, GR ;
FREIREICH, EJ .
ANNALS OF INTERNAL MEDICINE, 1982, 96 (02) :133-139
[10]   SOLID-PHASE EXTRACTION AND OPTIMIZED SEPARATION OF DOXORUBICIN, EPIRUBICIN AND THEIR METABOLITES USING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
NICHOLLS, G ;
CLARK, BJ ;
BROWN, JE .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1992, 10 (10-12) :949-957